Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...
Scientists said the drug trial of the treatment for melanoma could be the beginning of a transformation in care.
1h
'Cancer vaccines are coming': Merck, Moderna clear Phase 3 hurdle as Korean biotech joins the race
The messenger RNA (mRNA) technology that became humanity's frontline defense during the COVID-19 pandemic has now crossed a ...
WATE 6 On Your Side on MSN
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial
The study also met a secondary goal of preventing cancer from spreading to different parts of the body.
Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine.
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins ...
Moderna shares surged about 150% after Moderna and Merck reported positive Phase 3 results for a personalized mRNA treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results